GH Research's 2025 Update Highlights Progress but Lacks Critical Phase 3 Details

What happened

GH Research reported its full-year 2025 financial results, announcing the completion of its Phase 2b trial for GH001 in treatment-resistant depression and FDA clearance for U.S. clinical investigation. The company ended the year with $280.7 million in cash, cash equivalents, and marketable securities, providing a solid runway for upcoming activities. According to the DeepValue report, following the FDA's lift of a clinical hold in January 2026, the primary focus has shifted to securing alignment on Phase 3 design and initiating the pivotal program in 2026. However, this latest update does not disclose any new information on the Phase 3 protocol, device pharmacokinetic study completion, or a dated first-patient-in plan, which are critical de-risking milestones identified in the report. Consequently, while operational progress is noted, the valuation remains contingent on forthcoming details that are still opaque to investors.

Implication

The absence of Phase 3 design and device PK updates in this financial report means investors cannot yet underwrite the 2026 initiation timeline, leaving regulatory and execution uncertainties unresolved. While the strong cash position of $280.7 million reduces near-term dilution risk, any delays could accelerate burn and necessitate future financing, as highlighted in the DeepValue report's downside scenarios. Regulatory alignment with the FDA remains a key overhang, and without disclosed meeting outcomes or protocol parameters, the path forward lacks clarity, increasing volatility. Market sentiment may stay muted, as the narrative has shifted from hold-lift to execution, but visibility into that execution is still limited, echoing the report's emphasis on observable milestones. Therefore, maintaining a defensive stance is prudent until GH Research provides concrete evidence of Phase 3 readiness, such as FDA-aligned design and a dated start plan.

Thesis delta

The FY2025 results do not alter the core investment thesis; they merely update past achievements without advancing the critical Phase 3 readiness metrics identified in the DeepValue report. Investors should continue to monitor for FDA alignment and device PK completion as key catalysts, as the stock's valuation remains tied to these unresolved gating items.